6月3日-6日，2019美國生物技術大會暨展覽會（2019 Biotechnology Innovation Organization International Convention）在美國賓夕法尼亞州費城舉行，復宏漢霖以及復星醫藥集團亮相此次大會。
來訪者對復宏漢霖產品管線留下深刻印象
此次大會共吸引了逾1800位參展商以及17300多位全球行業領導者和頂級研究學者，他們在大會上與來自全球的生物製藥公司和醫藥公司共同探索合作共贏的潛在機遇。短短几天，復宏漢霖累計參與了190多場會面，同來自全球的合作商探討了在生物製品治療、技術平台、腫瘤免疫聯合療法等方面建立良好合作關係的可能性。不少合作商對復宏漢霖的產品管線、特別是首個獲批上市的中國國產生物類似葯漢利康®留下了深刻印象。
質高價優的治療方案受人矚目
復宏漢霖展台吸引了多位訪問者/組織機構前來拜訪，這其中不乏全球新葯研發組織和知名臨床研究機構。復宏漢霖聯合創始人、首席科學官姜偉東博士表示：「當談及質高價優的治療方案時，沒有人不會對之產生興趣。我們之間總能產生思維的碰撞，繼而探索更多持續的創新。」
當被問及復宏漢霖對將在聖地亞哥舉行的2020美國生物技術大會暨展覽會有何期待時，復宏漢霖商務拓展副總裁曹平女士表示，通過此次2019美國生物技術大會暨展覽會，復宏漢霖已與諸多美國和歐洲地區的潛在合作商建立了良好聯繫，相信2020美國生物技術大會暨展覽會也會為復宏漢霖繼續探索全球合作關係提供更多機會，同時也期待2020美國生物技術大會暨展覽會能回歸加利福尼亞州，復宏漢霖的美國研發中心也坐落於此。
復宏漢霖積極推動全球布局
近年來，復宏漢霖積極推動全球布局。研發方面，自2010年公司成立以來，復宏漢霖以全球聯動、整合創新為產品開發理念，在中國上海、台北和美國加州均設有研發實驗室，具備了兩岸三地技術互補的突出優勢。產品方面，其另一重磅產品HLX02（注射用曲妥珠單抗）已相繼在中國大陸、烏克蘭、歐盟波蘭和菲律賓全面啟動國際多中心3期臨床試驗，成為國內首個開展國際多中心3期臨床研究的生物類似葯，現已提交上市申請。憑藉領先的國際質量標準，復宏漢霖已與一些全球領先的醫藥公司達成戰略商業化合作，以透過合作夥伴既有的能力和資源迅速佔有海外市場份額。復宏漢霖與海外Accord、Cipla、Biosidus及Jacobson等公司簽訂了商業合作協議，對外授權覆蓋全球82個國家和地區。
未來，復宏漢霖也會持續探索更多國際化合作可能，在國際化的道路上繼續秉「質」前行，以優質生物葯，造福全球病患！
關於美國生物技術大會暨展覽會
美國生物技術大會暨展覽會(BIO International Convention)是全球最大的生物技術行業盛會，聚集了來自全球的業內領先生物製藥公司、投資商及合作商，並有諸多合作活動在大會期間舉行。大會由美國生物技術創新組織機構(Biotechnology Innovation Organization，以下簡稱「BIO」) 主辦，是代表生物技術公司、學術機構和相關機構的全球最大生物技術行業協會，其成員覆蓋美國和其他30個國家。BIO致力於為生物技術行業提供更多行業交流、合作機遇機會。
關於復宏漢霖
上海復宏漢霖生物技術股份有限公司為一家中國領先的生物製藥公司，致力於為全球患者提供質高價優的創新生物葯。自2010年成立以來，公司在中國上海、台北和美國加州均設有研發中心，已經建立並持續拓展全面的生物類似葯及生物創新葯產品管線，產品覆蓋腫瘤、自身免疫性疾病等領域。
截至目前，復宏漢霖13個產品、2個聯合治療方案已完成23項適應症的臨床試驗申請，累計獲得全球範圍內29個臨床試驗許可（中國大陸19個，中國台灣3個，美國3個，歐盟、澳大利亞、烏克蘭和菲律賓各1個）。其中，公司首款重磅產品漢利康®（利妥昔單抗注射液）已獲國家葯監局新葯上市註冊批准，成為中國首個獲批上市的生物類似葯。HLX03（阿達木單抗注射液）於2019年1月獲國家葯監局新葯上市申請受理，現已納入優先審評程序。HLX02（注射用曲妥珠單抗）相繼在中國大陸、烏克蘭、歐盟波蘭和菲律賓全面啟動國際多中心3期臨床試驗，成為國內首個開展國際多中心3期臨床研究的生物類似葯，於2019年4月獲國家葯監局新葯上市申請受理。
Henlius Attends BIO 2019
This past week, the Biotechnology Innovation Organization』s 2019 (BIO-2019) International Convention attracted more than 17,300 top biotech innovators, researchers and visionaries across the globe at the Pennsylvania Convention Center in Philadelphia. As one of the 1,800 exhibitors, Shanghai Henlius Biotech, Inc. (Henlius), along with Fosun Pharma (the parent company of Henlius), had an opportunity to connect with many biotechnology and pharmaceutical companies』 leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships at the convention. Through back-to-back scheduled meetings , Henlius ended with more than 190 meetings with national and international partners and multiple possible leads for in-licensing, research collaboration or commercial right out-licensing conducting at the Henlius』 booth over the course of three-day exhibition. These discussions were primarily focused on advancing new approaches to science, including therapeutic biologics, technology platforms, and immuno-oncology combinations, and building robust partnerships to accelerate innovation. A large majority of these potential future partners has confirmed their interest in continuing an in-depth conversion with Henlius after BIO-2019.
Since the first rituximab biosimilar being approved by China National Medical Products Administration (NMPA) on February 22, 2019, Henlius has been recognized as a rising star by many companies worldwide. Attendees who had previously not familiar with Henlius were quite impressed by its pipeline in both biosimilar and bio-innovative antibodies and expressed interests in collaborating with Henlius in a variety of ways. Dr. Weidong Jiang, Chief Scientific Officer and Co-Founder at Henlius, stated that 「there is no shortage of excitement, innovation or ideas, particularly when it comes to affordable and effective treatments」. Jiang agreed, noting that Henlius had a daily flow of 40+ interested visitors and organizations ranging from potential global drug developers to branding Clinical Research Organizations dropping by at the booth.
When Ms. Ping Cao, Vice President of Business Development at Henlius, was asked by the BIO organizer 「what will be the objective for Henlius at the next BIO-2020 in San Diego?」 Ping shared some words of excitement: with many productive meetings accomplished at BIO-2019, Henlius has made connections with a handful of potential collaborations and partnerships especially in the USA and Europe. Henlius purses every opportunity to help patients, caregivers, regulators and the industry as working together to impact affordability of effective treatments. BIO-2020 will be a great opportunity for Henlius to continue connecting with global partners. Henlius looks forward to welcoming the BIO-2020 back to California where one of its R&D facilities is located in the Bay Area.
Henlius pressed forward with global footprint in recent years. Since its inception in 2010, Henlius has built an integrated and efficient global R&D platform with key facilities in Shanghai, Taipei and California. The three R&D centers closely collaborate with each other to ensure a highly productive and cost-efficient R&D process. On the product side, HLX02 (trastuzumab injection), one of the major products, is the first biosimilar developed in China to enter a multi-jurisdictional Phase 3 clinical trial in China, Poland, Ukraine and the Philippines. HLX02 received a New Drug Application (NDA) acceptance from the NMPA in April, 2019. Moreover, with global quality standard, Henlius has proven track record of initiating strategic commercialisation collaborations with global leading pharmaceutical companies, which will enable Henlius to expeditiously capture market share through the established capabilities and partner resources. To this end, Henlius has entered into license and commercialisation agreements with multiple partners, including Accord, Cipla, Biosidus and Jacobson Medical. Henlius has entered into agreements for the licensing and commercialisation in over 82 jurisdictions and regions.